🎊 We’re honored to be selected as one of the six winning biotech companies in the 2025 Bayer Pharma China Open Innovation, announced during the Bayer Pharma China Open Innovation Day at Bayer Co.Lab in Shanghai.This recognition highlights our commitment to advancing next-generation immunotherapies for solid tumors, including our CDH17-targeted T cell engager, ARB202, and reflects the growing strength of innovation and collaboration within China’s biopharma ecosystem.A heartfelt thank you to Bayer Co.Lab for championing open innovation and fostering partnerships that accelerate scientific breakthroughs for patients worldwide.